血液検査の世界市場：技術（核酸増幅検査（NAT）、ELISA法、EIA法、CLIA法、次世代シーケンシング、ウエスタンブロット法）、試薬、装置...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.4 CURRENCY 22
1.5 LIMITATIONS 22
1.6 STAKEHOLDERS 22

2 RESEARCH METHODOLOGY 23
2.1 RESEARCH DATA 23
2.2 SECONDARY DATA 24
2.2.1 KEY DATA FROM SECONDARY SOURCES 24
2.3 PRIMARY DATA 25
2.3.1 KEY DATA FROM PRIMARY SOURCES 25
2.3.2 KEY INDUSTRY INSIGHTS 25
2.3.3 BREAKDOWN OF PRIMARIES 26
2.4 MARKET SIZE ESTIMATION 26
2.4.1 BOTTOM-UP APPROACH 26
2.4.2 TOP-DOWN APPROACH 27
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 28
2.6 MARKET SHARE ESTIMATION 29
2.7 ASSUMPTIONS FOR THE STUDY 29

3 EXECUTIVE SUMMARY 30

4 PREMIUM INSIGHTS 35
4.1 BLOOD SCREENING MARKET, BY TECHNOLOGY 35
4.2 BLOOD SCREENING MARKET, BY PRODUCTS AND SERVICES 36
4.3 BLOOD SCREENING REAGENTS MARKET 37
4.4 BLOOD SCREENING ELISA MARKET 38
4.5 BLOOD SCREENING MARKET, BY END USER 39
4.6 GEOGRAPHIC SNAPSHOT 40

5 MARKET OVERVIEW 41
5.1 INTRODUCTION 42
5.2 MARKET SEGMENTATION 42
5.2.1 BY TECHNOLOGY 42
5.2.2 BY PRODUCTS AND SERVICES 43
5.2.3 BY END USER 43
5.2.4 BY REGION 44
5.3 MARKET DYNAMICS 45
5.3.1 DRIVERS 45
5.3.1.1 Increasing number of blood donations and blood donors 45
5.3.1.2 Rising awareness regarding the safety of donated blood 46
5.3.1.3 Increasing affordability for NAT due to rising disposable incomes 46
5.3.1.4 Growing adoption of NAT for blood screening 46
5.3.1.5 Increasing demand of donated blood 46
5.3.1.6 Rising prevalence of infectious diseases 47
5.3.2 RESTRAINTS 48
5.3.2.1 Capital expenditure and operating costs of NAT 48
5.3.2.2 Lack of mandates for NAT in developing countries 49
5.3.2.3 Emergence of alternative technologies such as digital immunoassay 49
5.3.3 OPPORTUNITIES 50
5.3.3.1 Pathogen reduction technology 50
5.3.3.2 Microbiology screening 50
5.3.3.3 Multiplexing (single test for HIV, HBV, & HCV) 50
5.3.4 CHALLENGES 51
5.3.4.1 Price reduction 51
5.3.4.2 Lack of trained manpower 51
5.3.4.3 Regulatory challenges 51

6 INDUSTRY INSIGHTS 52
6.1 SUPPLY CHAIN ANALYSIS 52
6.2 PEST ANALYSIS 53
6.2.1 POLITICAL FACTORS 53
6.2.2 ECONOMIC FACTORS 53
6.2.3 SOCIAL FACTORS 54
6.2.4 TECHNICAL FACTORS 54
6.3 PORTER’S FIVE FORCE ANALYSIS 55
6.3.1 THREAT OF NEW ENTRANTS 55
6.3.2 THREAT OF SUBSTITUTE TECHNOLOGIES 56
6.3.3 BARGAINING POWER OF SUPPLIERS 56
6.3.4 BARGAINING POWER OF BUYERS 56
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 56

7 BLOOD SCREENING MARKET, BY TECHNOLOGY 57
7.1 INTRODUCTION 58
7.2 BLOOD SCREENING MARKET, BY VOLUME (NUMBER OF TESTS CONDUCTED) 59
7.3 NUCLEIC ACID TEST (NAT) 60
7.3.1 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA) 63
7.3.2 REAL-TIME POLYMERASE CHAIN REACTION (PCR) 65
7.4 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 68
7.4.1 RAPID TEST (CARD METHODOLOGY) 70
7.4.2 1ST GENERATION ELISA 72
7.4.3 2ND GENERATION ELISA 74
7.4.4 3RD GENERATION ELISA 76
7.4.5 4TH GENERATION ELISA 78
7.5 ENZYME IMMUNOASSAYS (EIAS) AND CHEMILUMINESCENT IMMUNOASSAYS (CLIAS) 81
7.6 NEXT-GENERATION SEQUENCING (NGS) 83
7.7 WESTERN BLOT ASSAY 85

8 BLOOD SCREENING MARKET, BY PRODUCTS AND SERVICES 88
8.1 INTRODUCTION 89
8.2 REAGENTS 90
8.2.1 ELISA REAGENTS 92
8.2.1.1 Immunosorbent 95
8.2.1.2 Controls 95
8.2.1.3 Conjugate (Antigen or antibody conjugated enzyme) 95
8.2.1.4 Substrate (Substrate of enzyme) 95
8.2.1.5 Sample diluents and wash solutions 96
8.2.2 NAT REAGENTS 96
8.2.2.1 Enzymes and Polymerases 99
8.2.2.2 Standards and Controls 99
8.2.2.3 Probes and Primers 99
8.2.2.4 Buffers, Nucleotides and Solutions 99
8.2.2.5 Labeling and Detection Reagents 99
8.2.3 OTHER REAGENTS 100
8.3 INSTRUMENTS (HARDWARE) 101
8.3.1 RENTAL PURCHASE 104
8.3.2 OUTRIGHT PURCHASE 104
8.4 SOFTWARE AND SERVICES 104

9 BLOOD SCREENING MARKET, BY END USER 107
9.1 INTRODUCTION 108
9.2 BLOOD BANKS 109
9.3 HOSPITALS 112

10 BLOOD SCREENING MARKET, BY REGION 115
10.1 INTRODUCTION 116
10.2 NORTH AMERICA 119
10.2.1 U.S. 122
10.2.2 CANADA 125
10.3 EUROPE 127
10.3.1 GERMANY 130
10.3.2 FRANCE 133
10.3.3 U.K. 136
10.3.4 ITALY 139
10.3.5 SPAIN 141
10.3.6 REST OF EUROPE (ROE) 145
10.4 ASIA 148
10.4.1 JAPAN 150
10.4.2 CHINA 153
10.4.3 INDIA 156
10.4.4 REST OF ASIA (ROA) 159
10.5 REST OF THE WORLD (ROW) 162

11 COMPETITIVE LANDSCAPE 166
11.1 OVERVIEW 166
11.2 MARKET SHARE ANALYSIS 167
11.2.1 MARKET SHARE ANALYSIS FOR NAT 167
11.2.2 MARKET SHARE ANALYSIS FOR BLOOD SCREENING 168
11.3 COMPETITIVE SITUATIONS AND TRENDS 169
11.3.1 NEW PRODUCT LAUNCHES 170
11.3.2 MERGERS AND ACQUISITIONS 171
11.3.3 REGULATORY APPROVALS 172
11.3.4 PARTNERSHIPS AND AGREEMENTS 173

12 COMPANY PROFILES 174
(Overview, Financials, Products & Services, Strategy, & Developments)*
12.1 INTRODUCTION 174
12.2 GRIFOLS 175
12.3 ROCHE DIAGNOSTICS (A DIVISION OF F. HOFFMANN-LA ROCHE LTD) 178
12.4 ABBOTT LABORATORIES 181
12.5 BIOMÉRIEUX 184
12.6 BIO-RAD LABORATORIES, INC. 187
12.7 SIEMENS HEALTHCARE (SUBSIDIARY OF SIEMENS AG) 190
12.8 ORTHO-CLINICAL DIAGNOSTICS, INC. 192
12.9 THERMO FISHER SCIENTIFIC, INC. 194
12.10 BECKMAN COULTER (SUBSIDIARY OF DANAHER CORPORATION) 196
12.11 BECTON, DICKINSON AND COMPANY 198
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

13 APPENDIX 200
13.1 INSIGHTS OF INDUSTRY EXPERTS 200
13.2 DISCUSSION GUIDE 201
13.3 AVAILABLE CUSTOMIZATIONS 204
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 204
13.5 RELATED REPORTS 205